Search Results - "Kathy H Fraeman"

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world by Shire, Norah J., Klein, Alyssa B., Golozar, Asieh, Collins, Jenna M., Fraeman, Kathy H., Nordstrom, Beth L., McEwen, Robert, Hembrough, Todd, Rizvi, Naiyer A.

“…Background Mutations in STK11 (STK11m) and frequently co-occurring KRAS mutations (KRASm/STK11m) are associated with poor survival in metastatic NSCLC (mNSCLC)…”
Get full text

Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis by Chenglong Han, Don W Robinson, Jr, Monica V Hackett, L Clark Paramore, Kathy H Fraeman, Mohan V Bala

“…OBJECTIVE: To compare the prevalence of cardiovascular diseases and their risk factors between patients with rheumatoid arthritis (RA), psoriatic arthritis…”
Get full text

Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study by Nordstrom, Beth L., Cai, Bin, De Gregorio, Fabio, Ban, Lu, Fraeman, Kathy H., Yoshida, Yuki, Gibbs, Trevor

“…Introduction: The primary aim of this study was to compare the incidence of venous thromboembolism (VTE) among women initiating ospemifene vs other selective…”
Get full text

Validation of Claims Algorithms for Progression to Metastatic Cancer in Patients with Breast, Non-small Cell Lung, and Colorectal Cancer by Nordstrom, Beth L, Simeone, Jason C, Malley, Karen G, Fraeman, Kathy H, Klippel, Zandra, Durst, Mark, Page, John H, Xu, Hairong

“…Validated algorithms for identifying progression to metastatic cancer could permit the use of administrative claims databases for research in this area. To…”
Get full text

Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study by Fraeman, Kathy H., Nordstrom, Beth L., Luo, Weixiu, Landis, Sarah H., Shantakumar, Sumitra

“…This retrospective cohort study was conducted to estimate incidence rates of new-onset hypertension in adult cancer patients identified from the Varian Medical…”
Get full text

Incidence of venous thromboembolism among postmenopausal women prescribed ospemifene, selective estrogen receptor modulators for noncancer indications, or untreated vulvar and vaginal atrophy by Nordstrom, Beth L., Cai, Bin, De Gregorio, Fabio, Dhalwani, Nafeesa, Fraeman, Kathy H., Yoshida, Yuki, Gibbs, Trevor

“…OBJECTIVE:Ospemifene is a nonsteroidal selective estrogen receptor modulator (SERM) for the treatment of moderate symptomatic vulvar and vaginal atrophy (VVA)…”
Get full text

Individualized HbA1c target selection and achievement in the Multinational Observational Study Assessing Insulin Use (MOSA1c) type 2 diabetes study by Caballero, A. Enrique, Nordstrom, Beth L., Liao, Birong, Fan, Ludi, Zhang, Nan, Fraeman, Kathy H., Perez-Nieves, Magaly

“…To identify which individual-, physician-, and the healthcare system-related factors can predict individualized hemoglobin A1c (HbA1c) targets and the…”
Get full text

Disruptions in Liver Function among Cancer Patients and Patients Treated with Tyrosine Kinase Inhibiting Drugs: Comparisons of Two Population-Based Databases by Landis, Sarah H., Nordstrom, Beth L., Sansbury, Leah B., Shantakumar, Sumitra, Laurent, Samantha A. St, Fraeman, Kathy H., Nelson, Jeanenne J.

“…Liver toxicity is a recognized adverse event associated with small molecule tyrosine kinase inhibitors (TKIs). Electronic Medical Record (EMR) databases offer…”
Get full text

Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network by Shantakumar, Sumitra, Nordstrom, Beth L., Djousse, Luc, Hall, Susan A., Gagnon, David R., Fraeman, Kathy H., van Herk-Sukel, Myrthe, Chagin, Karen, Nelson, Jeanenne

“…Purpose To quantify the hepatic safety of pazopanib and comparator anti-vascular endothelial growth factor (VEGF) therapies in clinical practice among renal…”
Get full text

Prescriber Compliance With Liver Monitoring Guidelines for Pazopanib in the Postapproval Setting: Results From a Distributed Research Network by Shantakumar, Sumitra, Nordstrom, Beth L, Hall, Susan A, Djousse, Luc, van Herk-Sukel, Myrthe P.P, Fraeman, Kathy H, Gagnon, David R, Chagin, Karen, Nelson, Jeanenne J

“…OBJECTIVESPazopanib received US Food and Drug Administration approval in 2009 for advanced renal cell carcinoma. During clinical development, liver chemistry…”
Get full text

Warfarin prophylaxis in patients after total knee or hip arthroplasty - international normalized ratio patterns and venous thromboembolism by Nordstrom, Beth L., Kachroo, Sumesh, Fraeman, Kathy H., Nutescu, Edith A., Schein, Jeff R., Fisher, Alan, Bookhart, Brahim K.

“…Abstract Objective: Warfarin is frequently used for the prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA/TKA). The current…”
Get full text

Patient outcomes associated with 2-octyl cyanoacrylate topical skin adhesive in coronary artery bypass graft surgery by Fraeman, Kathy H, Reynolds, Matthew W, Vaughn, Brian B, Hart, James C

“…Surgical site infection (SSI) is an important cause of morbidity and occasionally death after coronary artery bypass graft (CABG) surgery. These infections…”
Get more information

Estimating Costs of Care for Patients with Newly Diagnosed Metastatic Colorectal Cancer by Paramore, L. Clark, Thomas, Simu K., Knopf, Kevin B., Cragin, Lael S., Fraeman, Kathy H.

“…This study examines the resource use patterns and costs of care for patients with incident metastatic colorectal cancer (mCRC) based on analyses of…”
Get full text

Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter by Nordstrom, Beth L, Luo, Weixiu, Fraeman, Kathy, Whyte, Joanna L, Nordyke, Robert J

“…Prior to 2007, the erythropoiesis-stimulating agents (ESAs) epoetin alfa and darbepoetin alfa were indicated for use in chemotherapyinduced anemia to achieve…”
Get full text